Hemogenyx Pharmaceuticals PLC Announces Grant of Options

LONDON, UK / ACCESSWIRE / July 13, 2020 / Hemogenyx Pharmaceuticals plc (LSE:HEMO)(“Hemogenyx Pharmaceuticals” or the “Company”), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the Board of Directors has agreed to grant options over a total of 6,200,626 ordinary shares of 1p each in the capital of the Company (“Share Options”) to certain PDMRs and a member of the Scientific Advisory Board of the Company.

The details of the Share Options granted are set out below:

Name

Position

Number of Share Options Granted

Exercise Price (pence)

Vesting Date

Expiry Date

Peter Redmond

Non-Executive Director

2,200,000

7

Vesting in quarterly tranches over the 12 months from 13 July 2020

12 July 2025

Andrew Wright

Financial Controller (PDMR)

2,200,000

7

12 July 2025

Dr Alexander Tarakhovsky

Scientific Adviser

1,800,626

3.5

Immediate

3 October 2022

Following the grant of the Share Options, in aggregate there will be 36,753,702 ordinary shares of 1p each of the Company under option to directors, employees and members of the Scientific Advisory Board of the Company, representing 8.48% of the issued ordinary share capital of the Company.

Enquiries:

Hemogenyx Pharmaceuticals plc

www.hemogenyx.com

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder

[email protected]

Peter Redmond, Director

 
   
   
   

SP Angel Corporate Finance LLP

Tel: +44 (0)20 3470 0470

Matthew Johnson, Vadim Alexandre, Soltan Tagiev

 
   
   
   

Peterhouse Capital Limited

Tel: +44 (0)20 7469 0930

Lucy Williams, Duncan Vasey, Charles Goodfellow

 
   
   
   

US Media enquiries

Tel: +1 (323) 646-3249

Lowell Goodman

[email protected]

Notification and public disclosure of transactions by persons discharging managerial responsibilities (“PDMR”) and persons closely associated with them (“PCA”):

1.

Details of PDMR/person closely associated with them

a)

Name

1. Peter Redmond

2. Andrew Wright

b)

Position/status

1. Non-Executive Director

2. Financial Controller (PDMR, non-board)

c)

Initial notification/
amendment

Initial notification

2.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Options over ordinary shares of 1p of Hemogenyx Pharmaceuticals plc
Identification code GB00BYX3WZ24

b)

Nature of the transaction

Grant of options

c)

Price(s) and volume(s)

Price(s)

Volume(s)

1. £0.07

2. £0.07

1. 2,200,000

2. 2,200,000

d)

Aggregated information

– Aggregated volume

– Price

Price(s)

Volume(s)

N/A – variable

4,400,000

e)

Date of the transaction

13/07/2020

f)

Place of the transaction

Outside of a trading venue

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

SOURCE: Hemogenyx Pharmaceuticals PLC

View source version on accesswire.com:
https://www.accesswire.com/597270/Hemogenyx-Pharmaceuticals-PLC-Announces-Grant-of-Options

error: Content is protected !!